6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
described O
below O
and O
elsewhere O
in O
the O
labeling O
: O
* O
Suicidal B-OSE_Labeled_AE
Behavior I-OSE_Labeled_AE
and O
Ideation O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Dizziness B-OSE_Labeled_AE
and O
Ataxia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Cardiac B-OSE_Labeled_AE
Rhythm I-OSE_Labeled_AE
and O
Conduction O
Abnormalities I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Syncope B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Multiorgan B-OSE_Labeled_AE
Hypersensitivity I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Monotherapy O
: O
Most O
common O
adverse O
reactions O
are O
similar O
to O
those O
seen O
in O
adjunctive O
therapy O
studies O
( O
6.1 O
) O
* O
Adjunctive O
therapy O
: O
Most O
common O
adverse O
reactions O
( O
> O
=10 O
% O
and O
greater O
than O
placebo O
) O
are O
diplopia B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
UCB O
, O
Inc O
. O
at O
1-844-599-2273 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
the O
premarketing O
development O
of O
adjunctive O
therapy O
for O
partial B-Not_AE_Candidate
-onset O
seizures I-Not_AE_Candidate
, O
1327 O
patients O
received O
VIMPAT O
in O
controlled O
and O
uncontrolled O
trials O
, O
of O
whom O
1000 O
were O
treated O
for O
longer O
than O
6 O
months O
, O
and O
852 O
for O
longer O
than O
12 O
months O
. O

The O
monotherapy O
development O
program O
included O
425 O
patients O
, O
310 O
of O
whom O
were O
treated O
for O
longer O
than O
6 O
months O
, O
and O
254 O
for O
longer O
than O
12 O
months O
. O

VIMPAT O
Tablet O
and O
Oral O
Solution O
Monotherapy O
Historical-Control O
Trial O
( O
Study O
1 O
) O
* O
In O
the O
monotherapy O
trial O
, O
16 O
% O
of O
patients O
randomized O
to O
receive O
VIMPAT O
at O
the O
recommended O
doses O
of O
300 O
and O
400 O
mg/day O
discontinued O
from O
the O
trial O
as O
a O
result O
of O
an O
adverse O
reaction O
. O

The O
adverse O
reaction O
most O
commonly O
( O
> O
=1 O
% O
on O
VIMPAT O
) O
leading O
to O
discontinuation O
was O
dizziness B-OSE_Labeled_AE
. O

* O
Adverse O
reactions O
that O
occurred O
in O
this O
study O
were O
generally O
similar O
to O
those O
that O
occurred O
in O
adjunctive O
placebo-controlled O
studies O
. O

One O
adverse O
reaction O
, O
insomnia B-OSE_Labeled_AE
, O
occurred O
at O
a O
rate O
of O
> O
=2 O
% O
and O
was O
not O
reported O
at O
a O
similar O
rate O
in O
previous O
studies O
. O

This O
adverse O
reaction O
has O
also O
been O
observed O
in O
postmarketing O
experience O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Because O
this O
study O
did O
not O
include O
a O
placebo O
control O
group O
, O
causality O
could O
not O
be O
established O
. O

* O
Dizziness B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
and O
fatigue B-OSE_Labeled_AE
all O
occurred O
at O
lower O
incidences O
during O
the O
AED O
Withdrawal O
Phase O
and O
Monotherapy O
Phase O
, O
compared O
with O
the O
Titration O
Phase O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Adjunctive O
Therapy O
Controlled O
Trials O
( O
Studies O
2 O
, O
3 O
, O
and O
4 O
) O
* O
In O
adjunctive O
therapy O
controlled O
clinical O
trials O
, O
the O
rate O
of O
discontinuation O
as O
a O
result O
of O
an O
adverse O
reaction O
was O
8 O
% O
and O
17 O
% O
in O
patients O
randomized O
to O
receive O
VIMPAT O
at O
the O
recommended O
doses O
of O
200 O
and O
400 O
mg/day O
, O
respectively O
, O
29 O
% O
at O
600 O
mg/day O
, O
and O
5 O
% O
in O
patients O
randomized O
to O
receive O
placebo O
. O

The O
adverse O
reactions O
most O
commonly O
( O
> O
1 O
% O
on O
VIMPAT O
and O
greater O
than O
placebo O
) O
leading O
to O
discontinuation O
were O
dizziness B-OSE_Labeled_AE
, O
ataxia B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
diplopia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
, O
and O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
. O

* O
Table O
2 O
gives O
the O
incidence O
of O
adverse O
reactions O
that O
occurred O
in O
> O
=2 O
% O
of O
adult O
patients O
with O
partial B-Not_AE_Candidate
-onset O
seizures I-Not_AE_Candidate
in O
the O
VIMPAT O
total O
group O
and O
for O
which O
the O
incidence O
was O
greater O
than O
placebo O
. O

Table O
2 O
: O
Adverse O
Reactions O
Incidence O
in O
Adjunctive O
Therapy O
Pooled O
, O
Placebo-Controlled O
Trials O
in O
Patients O
with O
Partial-Onset O
Seizures O
( O
Studies O
2 O
, O
3 O
, O
and O
4 O
) O
System O
Organ O
Class/Preferred O
Term O
PlaceboN=364 O
% O
VIMPAT200 O
mg/dayN=270 O
% O
VIMPAT400 O
mg/dayN=471 O
% O
VIMPAT600 O
mg/dayN=203 O
% O
VIMPATTotalN=944 O
% O
Ear B-NonOSE_AE
and I-NonOSE_AE
labyrinth I-NonOSE_AE
disorder I-NonOSE_AE
Vertigo B-OSE_Labeled_AE
1 O
5 O
3 O
4 O
4 O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
Diplopia B-OSE_Labeled_AE
2 O
6 O
10 O
16 O
11 O
Blurred B-OSE_Labeled_AE
Vision I-OSE_Labeled_AE
3 O
2 O
9 O
16 O
8 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
4 O
7 O
11 O
17 O
11 O
Vomiting B-OSE_Labeled_AE
3 O
6 O
9 O
16 O
9 O
Diarrhea B-OSE_Labeled_AE
3 O
3 O
5 O
4 O
4 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
6 O
7 O
7 O
15 O
9 O
Gait B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
< O
1 O
< O
1 O
2 O
4 O
2 O
Asthenia B-OSE_Labeled_AE
1 O
2 O
2 O
4 O
2 O
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
Contusion B-OSE_Labeled_AE
3 O
3 O
4 O
2 O
3 O
Skin B-OSE_Labeled_AE
laceration I-OSE_Labeled_AE
2 O
2 O
3 O
3 O
3 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
8 O
16 O
30 O
53 O
31 O
Headache B-OSE_Labeled_AE
9 O
11 O
14 O
12 O
13 O
Ataxia B-OSE_Labeled_AE
2 O
4 O
7 O
15 O
8 O
Somnolence B-OSE_Labeled_AE
5 O
5 O
8 O
8 O
7 O
Tremor B-OSE_Labeled_AE
4 O
4 O
6 O
12 O
7 O
Nystagmus B-OSE_Labeled_AE
4 O
2 O
5 O
10 O
5 O
Balance B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
0 O
1 O
5 O
6 O
4 O
Memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
2 O
1 O
2 O
6 O
2 O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Depression B-OSE_Labeled_AE
1 O
2 O
2 O
2 O
2 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
1 O
3 O
2 O
3 O
2 O
The O
overall O
adverse O
reaction O
rate O
was O
similar O
in O
male O
and O
female O
patients O
. O

Although O
there O
were O
few O
non-Caucasian O
patients O
, O
no O
differences O
in O
the O
incidences O
of O
adverse O
events O
compared O
to O
Caucasian O
patients O
were O
observed O
. O

Laboratory O
Abnormalities O
* O
Abnormalities B-OSE_Labeled_AE
in O
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
have O
occurred O
in O
controlled O
trials O
with O
VIMPAT O
in O
adult O
patients O
with O
partial B-Not_AE_Candidate
-onset O
seizures I-Not_AE_Candidate
who O
were O
taking O
1 O
to O
3 O
concomitant O
anti-epileptic O
drugs O
. O

Elevations B-OSE_Labeled_AE
of O
ALT I-OSE_Labeled_AE
to O
> O
=3* O
ULN O
occurred O
in O
0.7 O
% O
( O
7/935 O
) O
of O
VIMPAT O
patients O
and O
0 O
% O
( O
0/356 O
) O
of O
placebo O
patients O
. O

One O
case O
of O
hepatitis B-OSE_Labeled_AE
with O
transaminases B-NonOSE_AE
> I-NonOSE_AE
2 I-NonOSE_AE
0 I-NonOSE_AE
* I-NonOSE_AE
ULN I-NonOSE_AE
occurred O
in O
one O
healthy O
subject O
10 O
days O
after O
VIMPAT O
treatment O
completion O
, O
along O
with O
nephritis B-OSE_Labeled_AE
( O
proteinuria B-NonOSE_AE
and O
urine B-NonOSE_AE
casts I-NonOSE_AE
) O
. O

Serologic O
studies O
were O
negative O
for O
viral B-NonOSE_AE
hepatitis I-NonOSE_AE
. O

Transaminases O
returned O
to O
normal O
within O
one O
month O
without O
specific O
treatment O
. O

At O
the O
time O
of O
this O
event O
, O
bilirubin O
was O
normal O
. O

The O
hepatitis B-NonOSE_AE
/ O
nephritis B-NonOSE_AE
was O
interpreted O
as O
a O
delayed B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
to O
VIMPAT O
. O

Other O
Adverse O
Reactions O
* O
The O
following O
is O
a O
list O
of O
adverse O
reactions O
reported O
by O
patients O
treated O
with O
VIMPAT O
in O
all O
clinical O
trials O
in O
patients O
with O
partial B-Not_AE_Candidate
-onset O
seizures I-Not_AE_Candidate
, O
including O
controlled O
trials O
and O
long-term O
open-label O
extension O
trials O
. O

Adverse O
reactions O
addressed O
in O
other O
tables O
or O
sections O
are O
not O
listed O
here O
. O

* O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
neutropenia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
* O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
palpitations B-OSE_Labeled_AE
* O
Ear B-NonOSE_AE
and I-NonOSE_AE
labyrinth I-NonOSE_AE
disorders I-NonOSE_AE
: O
tinnitus B-OSE_Labeled_AE
* O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
constipation B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
oral B-OSE_Labeled_AE
hypoaesthesia I-OSE_Labeled_AE
* O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
irritability B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
feeling B-OSE_Labeled_AE
drunk I-OSE_Labeled_AE
* O
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
: O
fall B-OSE_Labeled_AE
* O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
* O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
paresthesia B-OSE_Labeled_AE
, O
cognitive B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
hypoaesthesia B-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
, O
disturbance B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
, O
cerebellar B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
* O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
confusional B-OSE_Labeled_AE
state I-OSE_Labeled_AE
, O
mood B-OSE_Labeled_AE
altered I-OSE_Labeled_AE
, O
depressed B-OSE_Labeled_AE
mood I-OSE_Labeled_AE
VIMPAT O
Injection O
Adverse O
reactions O
with O
intravenous O
administration O
generally O
were O
similar O
to O
those O
that O
occurred O
with O
the O
oral O
formulation O
, O
although O
intravenous O
administration O
was O
associated O
with O
local O
adverse O
reactions O
such O
as O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
or O
discomfort O
( O
2.5 O
% O
) O
, O
irritation O
( O
1 O
% O
) O
, O
and O
erythema O
( O
0.5 O
% O
) O
. O

One O
case O
of O
profound O
bradycardia B-NonOSE_AE
( O
26 O
bpm O
: O
BP O
100/60 O
mmHg O
) O
occurred O
in O
a O
patient O
during O
a O
15-minute O
infusion O
of O
150 O
mg O
VIMPAT O
. O

This O
patient O
was O
on O
a O
beta-blocker O
. O

Infusion O
was O
discontinued O
and O
the O
patient O
experienced O
a O
rapid O
recovery O
. O

The O
safety O
of O
a O
15-minute O
loading O
dose O
administration O
of O
VIMPAT O
Injection O
200 O
mg O
to O
400 O
mg O
followed O
by O
oral O
administration O
of O
VIMPAT O
given O
twice O
daily O
at O
the O
same O
total O
daily O
dose O
as O
the O
initial O
intravenous O
infusion O
was O
assessed O
in O
an O
open-label O
study O
in O
patients O
with O
partial B-Not_AE_Candidate
-onset O
seizures I-Not_AE_Candidate
. O

Patients O
had O
to O
have O
been O
maintained O
on O
a O
stable O
dose O
regimen O
of O
1 O
to O
2 O
marketed O
antiepileptics O
for O
at O
least O
28 O
days O
prior O
to O
treatment O
assignment O
. O

Treatment O
groups O
were O
as O
follows O
: O
* O
Single O
dose O
of O
intravenous O
VIMPAT O
Injection O
200 O
mg O
followed O
by O
oral O
VIMPAT O
200 O
mg/day O
( O
100 O
mg O
every O
12 O
hours O
) O
* O
Single O
dose O
of O
intravenous O
VIMPAT O
Injection O
300 O
mg O
followed O
by O
oral O
VIMPAT O
300 O
mg/day O
( O
150 O
mg O
every O
12 O
hours O
) O
* O
Single O
dose O
of O
intravenous O
VIMPAT O
Injection O
400 O
mg O
followed O
by O
oral O
VIMPAT O
400 O
mg/day O
( O
200 O
mg O
every O
12 O
hours O
) O
. O

Table O
3 O
gives O
the O
incidence O
of O
adverse O
reactions O
that O
occurred O
in O
> O
=5 O
% O
of O
adult O
patients O
in O
any O
VIMPAT O
dosing O
group O
. O

Table O
3 O
: O
Adverse O
Reactions O
in O
a O
15-minute O
Infusion O
Study O
in O
Patients O
with O
Partial-Onset O
Seizures O
System O
Organ O
Class/Preferred O
Term O
VIMPAT O
200 O
mgN=25 O
% O
VIMPAT O
300 O
mgN=50 O
% O
VIMPAT O
400 O
mgN=25 O
% O
VIMPAT O
TotalN=100 O
% O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
Diplopia B-OSE_Labeled_AE
4 O
6 O
20 O
9 O
Blurred B-OSE_Labeled_AE
Vision I-OSE_Labeled_AE
0 O
4 O
12 O
5 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
0 O
16 O
24 O
14 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
0 O
6 O
12 O
6 O
Vomiting B-OSE_Labeled_AE
0 O
4 O
12 O
5 O
Oral B-OSE_Labeled_AE
Paresthesia I-OSE_Labeled_AE
4 O
4 O
8 O
5 O
Oral B-OSE_Labeled_AE
Hypoesthesia I-OSE_Labeled_AE
0 O
6 O
8 O
5 O
Diarrhea B-OSE_Labeled_AE
0 O
8 O
0 O
4 O
General B-NonOSE_AE
disorders I-NonOSE_AE
/ I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
0 O
18 O
12 O
12 O
Gait B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
8 O
2 O
0 O
3 O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
0 O
0 O
12 O
3 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
20 O
46 O
60 O
43 O
Somnolence B-OSE_Labeled_AE
0 O
34 O
36 O
26 O
Headache B-OSE_Labeled_AE
8 O
4 O
16 O
8 O
Paresthesia B-OSE_Labeled_AE
8 O
6 O
4 O
6 O
Tremor B-OSE_Labeled_AE
0 O
6 O
4 O
4 O
Abnormal B-OSE_Labeled_AE
Coordination I-OSE_Labeled_AE
0 O
6 O
0 O
3 O
Skin B-NonOSE_AE
& I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
0 O
6 O
4 O
4 O
Hyperhidrosis B-OSE_Labeled_AE
0 O
0 O
8 O
2 O
Adverse O
reactions O
that O
occurred O
with O
infusion O
of O
VIMPAT O
200 O
mg O
over O
15-minutes O
followed O
by O
VIMPAT O
100 O
mg O
administered O
orally O
twice O
per O
day O
were O
similar O
in O
frequency O
to O
those O
that O
occurred O
in O
3-month O
adjunctive O
therapy O
controlled O
trials O
. O

Considering O
the O
difference O
in O
period O
of O
observations O
( O
1 O
week O
vs O
. O
3 O
months O
) O
, O
the O
incidence O
of O
CNS O
adverse O
reactions O
, O
such O
as O
dizziness B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
and O
paresthesia B-OSE_Labeled_AE
may O
be O
higher O
with O
15-minute O
administration O
of O
VIMPAT O
Injection O
than O
with O
administration O
over O
a O
30-to O
60-minute O
period O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
VIMPAT O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Agranulocytosis B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
Aggression B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
hallucination B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
psychotic B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Angioedema B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
. O

